Dynamic 18F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer

Dynamic 18F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer

Abstract Major pathological response (MPR) is a potential surrogate for overall survival. We determined whether the dynamic changes in 18F‐labeled fluoro‐2‐deoxyglucose positron emission tomography/computed tomography (18F‐FDG PET/CT) were associated with MPR in patients receiving neoadjuvant immuno...

Full description

Bibliographic Details
Main Authors: Zhi‐Yong Chen, Rui Fu, Xiao‐Yue Tan, Li‐Xu Yan, Wen‐Fang Tang, Zhen‐Bin Qiu, Yi‐Fan Qi, Yu‐Fa Li, Qing‐Yi Hou, Yi‐Long Wu, Wen‐Zhao Zhong, Ben‐Yuan Jiang
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Thoracic Cancer
Subjects:
18F‐FDG PET/CT
immunotherapy
major pathological response
neoadjuvant therapy
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14562

Internet

https://doi.org/10.1111/1759-7714.14562

Similar Items